Apigenin: The Definitive Guide

What is Apigenin?

Apigenin is a flavone found in parsley, celery and chamomile. A small human pharmacokinetic study administered one isolated-aglycone exposure, but it did not test sleep or establish a bedtime regimen. A 2024 sleep-and-aging review maps human sleep evidence to apigenin-containing chamomile preparations rather than isolated apigenin capsules. Mechanistic and animal findings remain indirect for a retail sleep claim. [1], [3]

Typical Apigenin Protocols

These rows reproduce sources. Do not average them into one universal regimen.

Which forms and label details matter?

Distinguish free apigenin from glycosides such as apiin and apigenin glucosides in food or tea. Also record formulation and excipients: absorption from a parsley matrix, chamomile tea and an isolated capsule cannot be assumed equivalent.

How should it be stored?

Follow the finished-product label. Keep the container closed, dry and protected from heat and light; teas, tinctures and extracts can have different storage directions.

What is it commonly used for?

Isolated apigenin is marketed for sleep, relaxation, healthy aging and inflammation. Human evidence includes one tiny, acute isolated-aglycone pharmacokinetic arm plus food-matrix and chamomile studies; none establishes sleep efficacy for an isolated bedtime capsule.

What does human research show?

Borges administered 191 μmol of isolated apigenin aglycone, about 51.6 mg, once to three healthy men. Only 0.5% of the intake appeared as measured conjugates in 0–24-hour urine. The study measured pharmacokinetics, not sleep, and industry funding and conflicts were reported. Its additional parsley and chamomile arms produced different absorption timing and urinary recovery, showing why chemical form and matrix matter. [3] Meyer gave 11 healthy adults a single parsley bolus after a flavone-free diet. Apigenin peaked in plasma on average about 7.2 hours later, and 0.22% of the ingested amount appeared in 24-hour urine; this was also pharmacokinetics, not efficacy. [2] In a randomized crossover feeding study, 18 volunteers consumed 5 g dried parsley supplying 84 mg apigenin/day for seven days; measured hemostasis variables did not change significantly. [4] Zick’s chamomile trial used three 90 mg tablets twice daily. Each tablet was specified at a minimum 2.5 mg apigenin and later measured at 3.9 mg; primary sleep outcomes were null, and the multiconstituent preparation cannot be treated as isolated apigenin. [5] No verified randomized human sleep-efficacy trial of isolated oral apigenin was located in this current review.

How might it act?

Human pharmacokinetic work recovered glucuronide and sulfate metabolites after oral exposure and found poor absorption of the free parent compound. GABA-receptor and CD38 findings come mainly from laboratory and animal models. These observations explain research interest but do not validate a 25 mg, 50 mg or other bedtime dose.

How does it compare with related products?

What are the risks and interactions?

Short-term safety of isolated concentrated apigenin is not well defined in human trials. In-vitro work suggests possible effects on drug-metabolizing enzymes and transporters, but clinical magnitude is uncertain. Review anticoagulants, narrow-therapeutic-index medicines, sedatives, hormone therapies, chemotherapy, pregnancy and breastfeeding with a pharmacist or clinician. [6]

Which medicines require review?

Do not convert an in-vitro enzyme result into a precise separation interval. Bring the exact formulation and dose to a pharmacist, especially when medicine exposure must stay within a narrow range.

Regulatory status: In the United States, supplements generally lack premarket efficacy approval. In Canada, verify the finished product’s NPN or DIN-HM and licensed conditions. [7], [8]

What should be monitored?

Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, meals, symptoms, medicines, chosen outcome and review date.

What happens when it is stopped?

No ingredient-specific withdrawal syndrome is established. Record the stop date and compare the same sleep and next-day measures rather than changing several products at once.

Seek prompt care for a serious allergic reaction, unusual bleeding, persistent palpitations, chest pain or another severe symptom.

What do public communities report?

Public reports commonly mention relaxation, vivid dreams, morning grogginess or no effect. Those reports rarely verify species, extract, co-ingredients or sleep diagnosis, so they generate tracking questions rather than efficacy estimates.

Common questions about Apigenin

Has isolated apigenin been proven to improve human sleep?

No verified randomized oral sleep-efficacy trial of isolated apigenin was located in the current review.

Can chamomile trials prove apigenin works?

No. Chamomile contains many constituents and its preparation cannot be reduced to one molecule.

Is 50 mg a clinically established bedtime dose?

No. About 51.6 mg appeared once in a three-person pharmacokinetic arm, but that study did not test sleep or establish a bedtime dose.

Why include parsley studies?

They show human absorption and metabolism while also demonstrating that a food-exposure study is not an efficacy trial.

Is apigenin absorbed the same from every source?

No. Glycoside form and the parsley, tea or supplement matrix can change absorption and metabolism.

What should I track?

Free or glycoside form, formulation, amount each time, timing, co-ingredients, sleep and next-day outcomes, medicines and adverse effects.

Glossary

Terms for reading the evidence.

Preparation identity

Species or compound, plant part, extraction, ratio and standardization that define the tested product.

Amount per administration

Amount consumed at one time, distinct from daily total.

PSQI

Pittsburgh Sleep Quality Index, a self-reported questionnaire rather than an objective sleep recording.

ISI

Insomnia Severity Index, a symptom questionnaire used to rate perceived insomnia severity.

Monotherapy

The ingredient was tested without another active intervention.

Traditional use

A regulatory category based on long-standing use; it is not equivalent to efficacy established by modern randomized trials.

How this guide was researched

Accessible official sources and human reports were read on October 9, 2026. Titles, authors, journals, DOI, PMID and visible corrections were checked. An unreported frequency was not guessed.

How this guide was made

Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.

Explore the sources